New cancer drug KK2260 enters first human tests
NCT ID NCT06248411
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new drug called KK2260 in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test different dosing schedules in patients with esophageal or head and neck cancers. About 189 participants will be enrolled to evaluate safety, side effects, and early signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KK2260 (an experimental drug given intravenously)
- What this could lead to
- If successful, this could lead to a new treatment option for people with advanced solid tumors, including esophageal and head and neck cancers.
- What could go wrong
- This is a very early, first-in-human study with a small number of participants. The drug may not work or could cause unexpected side effects. It will take years before any potential treatment is available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aichi Cancer Center Hospital
RECRUITINGNagoya, Aichi-ken, 464-8681, Japan
-
Hiroshima University Hospital
RECRUITINGHiroshima, Hiroshima, 734-8551, Japan
-
Kanagawa Cancer Center
RECRUITINGYokohama, Kanagawa, 241-8515, Japan
-
Kobe University Hospital
RECRUITINGKobe, Hyōgo, 650-0017, Japan
-
Kumamoto University Hospital
RECRUITINGKumamoto, Kumamoto, 860-8556, Japan
-
Kyushu Cancer Center
RECRUITINGFukuoka, 811-1347, Japan
-
National Cancer Center Hospital
RECRUITINGChuo-ku, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
RECRUITINGKashiwa, Chiba, 277-8577, Japan
-
Osaka International Cancer Institute
RECRUITINGOsaka, 540-0008, Japan
-
Saitama Cancer Center
RECRUITINGShinden, Saitama, 362-0806, Japan
-
Shikoku Cancer Center
RECRUITINGMatsuyama, Ehime, 791-0280, Japan
-
Shizuoka Cancer Center
RECRUITINGNagaizumi-cho, Shizuoka, 411-8777, Japan
-
The Cancer Institute Hospital of JFCR
RECRUITINGKoto-ku, Tokyo, 135-8550, Japan
-
Tohoku University Hospital
RECRUITINGSendai, Miyagi, 980-8574, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a new drug combo shrink Hard-to-Treat tumors?